Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 1413 – June 2013

Ceftaroline fosamil (Zinforo®) 600 mg powder for concentration for solution for infusion

Submission by AstraZeneca UK Ltd

Recommendation of the All Wales Medicines Strategy Group

Ceftaroline fosamil (Zinforo®) is recommended as an option for restricted use within NHS Wales.

Ceftaroline fosamil (Zinforo®) should be restricted to use for the treatment of complicated skin and soft tissue infections in patients where methicillin-resistant *S. aureus* (MRSA) is suspected, only in the following settings:

- **For infections caused by Gram-positive pathogens, only if intravenous (IV) vancomycin or IV teicoplanin is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin or IV linezolid is normally used.**
- **For mixed infections caused by common Gram-positive and Gram-negative pathogens (excluding extended-spectrum beta-lactamase-producing organisms, AmpC-producing organisms and non-fermenter Gram-negative organisms, such as *Pseudomonas aeruginosa*), only if IV vancomycin in combination with IV co-amoxiclav or IV teicoplanin in combination with IV co-amoxiclav is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin in combination with IV co-amoxiclav or IV linezolid in combination with IV co-amoxiclav is normally used.**

Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of complicated skin and soft tissue infections outside of these settings.

Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of community-acquired pneumonia.

Additional note:

- The use of ceftaroline fosamil (Zinforo®) should be directed by microbiologists and infectious disease physicians only, and in line with antimicrobial stewardship policies in Wales.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1065), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.